Sino American biotech BeiGene (Nasdaq: ONC; HKEX: 06160), a global oncology company that will change its name to BeOne Medicines, today announced financial results and corporate updates from the first quarter 2025.
Revenue for the first quarter of 2025 was $1.1 billion, up 46.3% compared to $752 million in the prior-year period driven primarily by growth in Brukinsa (zanubrutinib) product sales in the USA and Europe.
US sales of Brukinsa totaled $563 million, representing growth of 60% over the prior-year period driven primarily by demand, with more than 60% of the quarter-over-quarter growth coming from expanded use in chronic lymphocytic leukemia (CLL) as Brukinsa continued to gain share as the sales in Europe totaled $116 million in the first quarter, representing growth of 73% compared to the prior-year period, driven by increased market share across all major European markets, including Germany, Italy, Spain, France and the UK.
https://www.thepharmaletter.com/beigene-posts-46-percent-st-qtr-sales-growth-bit-misses-consensus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.